Smouldering myeloma explained: watchful waiting, risk, and early treatment decisions

Short summary

Smouldering myeloma is an early warning stage in which certain bone marrow cells behave abnormally, but without organ damage. The article uses BBC presenter Lauren Laverne’s diagnosis to illustrate how doctors distinguish smouldering myeloma from cancer and why immediate treatment is not always necessary. It explains how plasma cells produce a monoclonal protein that can be measured in the blood, and how risk patterns help guide care. Routine screening is not recommended, but regular monitoring can catch progression early so treatment can be started at the most beneficial moment.

• Smouldering myeloma is a grey zone between health and active myeloma.
• Management relies on careful monitoring rather than universal early treatment.
• Risk patterns and genetic markers help predict progression, though predictions are not exact for individuals.
• Early therapy is being explored in high-risk cases, but decisions are tailored to the patient.

Original publisher: The Conversation

Overview

The article centers on smouldering myeloma, a condition that sits between health and active blood cancer. It begins with the real‑world example of BBC presenter Lauren Laverne, whose diagnosis is described as more nuanced than the word myeloma implies. Smouldering myeloma is characterized by a clonal plasma cell population that raises monoclonal protein levels without evident organ damage. While it is not a fully developed blood cancer, the condition signals a higher risk of progression to symptomatic disease, making close monitoring essential.

What smouldering myeloma is and where it comes from

Inside bone marrow, plasma cells produce antibodies. In myeloma, a single rogue plasma cell expands uncontrollably and creates many identical copies, yielding a monoclonal protein measurable in the blood. Over time, this cancerous process can crowd out normal blood production and injure bones, kidneys, and the immune system. Smouldering myeloma represents a halfway point where there is a detectable clone and elevated monoclonal protein, but no current organ damage. The patient often feels well, and the disease has not yet produced the classic symptoms of anaemia, bone pain, or infections.

Risk, monitoring, and the unpredictability of progression

Doctors assess risk by examining blood tests, bone marrow findings, and sometimes genetic signatures in plasma cells. Higher monoclonal protein levels, more extensive marrow involvement, and certain high‑risk markers raise the likelihood of progression. Conversely, lower‑risk cases may stay stable for years. However, even the best risk scores cannot predict with certainty what will happen to an individual, which is why ongoing surveillance is crucial.

Watchful waiting versus early treatment

Today’s standard approach is watchful waiting: regular blood and urine tests, kidney function checks, calcium and red blood cell counts, and occasional imaging or bone marrow reassessment when results suggest a shift. Treating all smouldering cases as active myeloma would expose many people to unnecessary drug side effects and the psychological burden of treatment. Yet, researchers are exploring whether early therapy might benefit higher‑risk smouldering cases, using combinations of tablets and targeted antibodies to delay progression and prolong symptom‑free periods.

Practical takeaways for patients and the public

Smouldering myeloma is uncommon and typically detected after an abnormal blood result prompts further tests. Routine screening in healthy individuals is not advised. For those diagnosed, the message is vigilance and informed decision‑making rather than alarm. Regular follow‑up allows clinicians to act promptly if progression occurs, while advances in myeloma therapy continue to improve outcomes should progression occur.

Original publisher: The Conversation